کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3909604 1251220 2009 4 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی زنان، زایمان و بهداشت زنان
پیش نمایش صفحه اول مقاله
Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer
چکیده انگلیسی

Sunitinib malate (SUTENT®) is an oral, multitargeted tyrosine kinase inhibitor that blocks several pathways central to angiogenesis and tumor cell proliferation and migration, including vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs). Sunitinib has demonstrated clinical activity as a single agent in patients with metastatic breast cancer and it is hypothesized that enhanced clinical benefit may be derived by combining sunitinib with chemotherapy or other targeted agents. The current report describes four patients with advanced/metastatic breast cancer who experienced clinically meaningful responses following treatment with sunitinib in combination with docetaxel.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: The Breast - Volume 18, Issue 4, August 2009, Pages 259–262
نویسندگان
, , ,